ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorEdwards Lifesciences

About this trial

The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater risk with a failing aortic bioprosthetic valve.

Eligibility criteria

Qualifiers

Failing aortic bioprosthetic valve demonstrating ≥ moderate stenosis and/or ≥ moderate insufficiency

Bioprosthetic valve size suitable for SAPIEN X4 THV

NYHA functional class ≥ II

Heart Team agrees the subject is at high or greater surgical risk

Disqualifiers

Anatomical characteristics that would preclude safe femoral placement of the introducer sheath or safe passage of the delivery system

Failing valve has moderate or severe paravalvular regurgitation

Failing valve is unstable, rocking, or not structurally intact

Known severe patient-prosthesis mismatch or bioprosthetic valve with residual mean gradient > 20 mmHg at the end of the index procedure for implantation of the original valve

Trial design

Treatments tested in this trial

  • SAPIEN X4 THV

Treatment groups

200 Participants
are divided into 2 treatment groups

Sponsors and collaborators